MTOR and colonic neoplasm: We found that PIK3CA mutation frequency was also significantly different in the three sub-clusters of colon cancer cells (Figure 3A), so we tested the sensitivity of PI3K-mTOR signaling pathway inhibitors in different sub-clusters of colon cancer cells.